Estradiol in men: the marker most GP panels skip — and why you shouldn't

What estradiol actually is, in 90 seconds

Estradiol (E2) is the principal oestrogen in men. It is made primarily by aromatisation of testosterone via the enzyme aromatase, with the bulk of conversion happening in adipose tissue, the brain, and the testes themselves.

That last word is important: estradiol is not "a female hormone with the wrong label." It has direct, essential roles in male physiology. Knockout-mouse models and rare humans with aromatase deficiency tell the same story: without functional estradiol signalling, men suffer poor bone density, impaired lipid metabolism, reduced libido, and disrupted negative-feedback control of LH and FSH.

In a healthy man, ~80% of circulating estradiol comes from aromatisation of testosterone. That is why E2 cannot be interpreted alone — it is downstream.

Why most standard panels skip it

If you ask a GP for a "hormone test" in Germany or the UK, you will usually walk out with total testosterone alone — sometimes FSH and LH, often nothing else. Estradiol is rarely on the order set. Three reasons:

1. Cultural framing. E2 is taught as a female-cycle hormone. In a man with no overt feminisation signs, it doesn't make the differential.
2. Cost discipline. Public-payer reimbursement codes for "fertility-relevant male workup" rarely include E2; ordering it requires a clinical justification many GPs aren't trained to write.
3. Interpretation difficulty. E2 is sensitive to body composition, age, hour of day, and assay technique. A clinician who isn't comfortable reading it will often skip it.

This is the diagnostic gap we see most often when men send us their previous GP results before ordering a panel. They have a testosterone number they have been told is fine; nobody has read the estradiol that explains why they still feel terrible.

What too high actually looks like

Elevated E2 in a man is most often a downstream effect of:

• Higher body fat (most adipose tissue aromatase),
• High-dose exogenous testosterone (more substrate for aromatisation),
• Liver disease (impaired clearance),
• Aging (gradually rising aromatase expression).

The clinical signature is unhelpful in isolation — water retention, gynaecomastia, mood lability, libido changes, reduced erection quality — because every one of those overlaps with low testosterone, sleep debt, or depression. The point of measuring E2 is to separate them.

A common pattern: a 38-year-old man, BMI 29, sees his GP for low libido. Total T comes back at 380 ng/dL — flagged as low-normal. He's offered TRT. He starts at a moderate dose. His libido improves for six weeks, then worsens. He gets puffier. His mood is volatile. Nobody has measured E2. When eventually drawn, it's at 65 pg/mL — well above range. The fix isn't more testosterone or starting an aromatase inhibitor; it is reading the picture in the first place and likely losing 5–10 kg of body fat before any TRT discussion.

What too low looks like — the modern problem

The high-E2 picture has been recognised for decades. The newer problem, post-2018 or so, is iatrogenically low E2 — caused by aggressive aromatase-inhibitor (AI) use in informal TRT and bodybuilding contexts.

Anastrozole and similar AIs were developed for breast cancer treatment in women. Their use in men is technically off-label and is now epidemic in TRT-adjacent communities, where the working assumption is "low E2 is good, lower is better." It is wrong, and the symptom picture is distinctive:

• Libido drops despite a high or supraphysiological testosterone level.
• Joint pain — knees, shoulders, hands — that men often blame on training volume.
• Mood crash — depressive symptoms, irritability, anhedonia.
• Erection quality drops, often more than testosterone alone predicts.
• Bone-density loss over time, invisible until a DEXA or a fracture.

This pattern is reversible: stopping the AI restores E2 within weeks, and most symptoms follow within one to two months. The reason men miss it is that the symptoms read like "TRT isn't working," and the reflex on a TRT forum is to add or increase the AI.

Reference ranges, with assay caveats

The adult male reference range is roughly 11.3–43.2 pg/mL (40–160 pmol/L), with meaningful variation by assay technique. Immunoassays read slightly higher than LC-MS/MS (mass-spectrometry); the gold-standard method is LC-MS/MS for low values, where immunoassays are known to over-report.

Two practical implications:

• A 25 pg/mL reading on an immunoassay and a 25 pg/mL reading on LC-MS/MS are not the same number. Lab method matters.
• Single readings have ~15–25% intra-individual variability. A borderline value warrants a repeat before any action.

How E2 reads on the Hormone Panel 01

On a full six-marker panel, estradiol is interpreted alongside:

• Total testosterone — the substrate for aromatisation. High T + high E2 is a known pattern. Low T + high E2 (typical in higher body fat) is the more common one in middle-aged men.
• SHBG — relevant because SHBG binds both T and E2. Very high SHBG can leave free E2 inadequate even with total E2 in range.
• LH and FSH — high E2 contributes to the negative-feedback signal that suppresses pituitary output. A man with chronically high E2 will often see his LH and FSH drift down.

The result is a multidimensional read: not just "is E2 in range," but "is the E2 you have appropriate for your testosterone, your body composition, and your axis state?" That is the question that decides whether the intervention is testosterone, body composition, an AI (rarely), or no intervention at all.

What to do with the number

If your E2 is high, the first conversation is body composition and lifestyle, not medication. A 5–8% body-fat reduction in higher-body-fat men typically moves E2 more than any pharmacological intervention available without a script.

If your E2 is low, particularly with low libido and no recent change in body fat, ask whether anything you have started or stopped in the last 90 days could be acting as an aromatase inhibitor. The list includes prescription AIs, certain over-the-counter "estrogen blocker" supplements, and a small number of medications used for other indications.

If your E2 is in range with persistent symptoms, the marker is not the issue — look elsewhere.

The marker most GP panels skip is the marker most likely to explain what you are feeling. Reading it is the easy part; the difficulty is getting it ordered in the first place.

Sources cited: Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism, 2018; full entry on /science.